anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Potassium Chloride Extended-release Tablets, USP are a solid oral dosage form of potassium chloride. Each contains 600 mg or 750 mg of potassium chloride equivalent to 8 mEq or 10 mEq of potassium in a wax matrix tablet.

Potassium Chloride Extended-release Tablets, USP are an electrolyte replenisher. The chemical name is potassium chloride, and the structural formula is KCl. Potassium chloride, USP is a white, granular powder or colorless crystals. It is odorless and has a saline taste. Its solutions are neutral to litmus. It is freely soluble in water and insoluble in alcohol.

Inactive Ingredients: Paraffin wax pastilles, ethylcellulose, triethyl citrate, colloidal silicon dioxide, and magnesium stearate. White tablets also contain polyvinyl alcohol, titanium dioxide, polyethylene glycol 3350, and talc. Yellow tablets also contain polyvinyl alcohol, talc, titanium dioxide, polyethylene glycol, D&C Yellow No. 10 aluminum lake, and FD&C Yellow No. 6 aluminum lake.

FDA approved dissolution test specifications differ from USP

FDA approved acceptance criteria for assay differs from USP test
BACKGROUND AND AIMS: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) of unknown cause. Alterations in one-carbon metabolism have impact in the pathophysiology by genetic susceptibility to MS and increased the risk of MS. The aim of this study was to investigate the contribution of the gene polymorphism on Methylenetetrahydrofolate Reductase (MTHFR), Methionine Synthase Reductase (MTRR), Methionine Synthase (MTR) enzymes and of the essential factors (homocysteine, Hcy; cysteine, Cys; and vitamin B12, VitB12) in folate metabolism.
METHODS: Eligible MS patients (n = 147) and health controls (n = 127) were participated. The gene polymorphisms were analyzed by Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) and the levels of plasma Hcy, Cys and VitB12 were measured by Enzyme Linked Immunuabsorbent Assay (ELISA).
RESULTS AND CONCLUSION: Our results showed that the levels of Hcy and VitB12 were lower and the levels of Cys were higher in MS compared to controls. The observation of high Cys values in all 3 gene polymorphisms suggests that the transsulfiration pathway of Hcy is directed towards Cys formation since the methionine synthesis pathway does not work. We could not find any association with all gene polymorphisms with the risk of MS. The T allele of MTHFR C677T and G allele of MTR A2756G are risk factors for serum Cys level on MS. As for MTR A2756G, serum vitB12 was observed in MS patients with G allele.
Chronic obstructive pulmonary disease(COPD) is a preventable and treatable illness, which is clinically characterized by persistent airflow limitation that is usually progressive. It's well known that airflow limitation lead to air trapping particularly during exercise, resulting in increased dyspnea and limitation of exercise capacity. Thus, COPD patients often unconsciously adopt a sedentary lifestyle, probably due to distressing exertional dyspnea. The sedentarism results in physical deconditioning and alterations of the peripheral muscles, and the latter one causes more exertional dyspnea and fatigue, which in turn leads to much more sedentarism, forming the vicious cycle of sedentarism, dyspnea/fatigue and more sedentarism. Thereby, measures should be taken to interrupt this vicious cycle. Some previous studies suggested that niv acting as an add-on therapy could help unloading the inspiratory muscle, reducing the dynamic compression of the airway, diminishing the dynamic hyperinflation,to some extent, relieved dyspnea during exercise in COPD patients. However,those measures were taken during exercise, acting as an add-on therapy. Whether NIV can play a role as a rescue therapy to relieve exertional dyspnea while the patients are already undergoing optimal treatment with bronchodilator and anti-inflammatory medication is still not quite clear. Therefore, we hypothesize that niv as a rescue-therapy has the same effect on relieving dyspnea in stable severe COPD patients just like the add-on therapy.
The diagnostic odysseys for rare disease patients are getting shorter as next-generation sequencing becomes more widespread. However, the complex genetic diversity and factors influencing expressivity continue to challenge accurate diagnosis, leaving more than 50% of genetic variants categorized as variants of uncertain significance.Genomic expression intricately hinges on localized interactions among its products. Conventional variant prioritization, biased towards known disease genes and the structure-function paradigm, overlooks the potential impact of variants shaping the composition, location, size, and properties of biomolecular condensates, genuine membraneless organelles swiftly sensing and responding to environmental changes, and modulating expressivity.To address this complexity, we propose to focus on the nexus of genetic variants within biomolecular condensates determinants. Scrutinizing variant effects in these membraneless organelles could refine prioritization, enhance diagnostics, and unveil the molecular underpinnings of rare diseases. Integrating comprehensive genome sequencing, transcriptomics, and computational models can unravel variant pathogenicity and disease mechanisms, enabling precision medicine. This paper presents the rationale driving our proposal and describes a protocol to implement this approach. By fusing state-of-the-art knowledge and methodologies into the clinical practice, we aim to redefine rare diseases diagnosis, leveraging the power of scientific advancement for more informed medical decisions.
Participants will orally take the herbal formula granules 12g twice a day for 4 weeks. No other interventions during the study period will be allowed.
Patients receive one or two treatment courses of MabThera®, each consisting of two 1000 mg i.v. infusions at an interval of 14 days. Investigational drug will be administered at Day 1 and Day 15, and, if patient is eligible for re-treatment, also at Week 24 and Week 26.
Sham treatment will consist of 6 seconds a minute for 30 minutes a day, 5 days a week for 2 weeks (double blind phase only) using a sham device. Sham device mimics the same noise and sensation of active treatment.
<P>PROBLEM TO BE SOLVED: To provide cosmetic powder having excellent ultraviolet-shielding effect and inflammation suppressing effect in irradiation at high light quantity and a cosmetic containing the powder.  <P>SOLUTION: The powder for cosmetic is produced by using sericite as a substrate powder and coating the substrate with a compound metal oxide composed mainly of titanium dioxide fine particles. The constitution components of the compound metal oxide are preferably silicon and aluminum in addition to titanium. The coated powder is preferably subjected to surface treatment such as coating with metal soap and the introduction of a perfluoroalkyl group. Since the powder produced by the method has excellent ultraviolet-shielding action, especially under the irradiation with ultraviolet rays at a high dose, the cosmetic containing the powder is suitable as an ultraviolet-protecting cosmetic.  <P>COPYRIGHT: (C)2004,JPO&NCIPI
<P>PROBLEM TO BE SOLVED: To provide a medicine for swine atrophic rhinitis comprising a recombinant dermonecrotic toxoid.  <P>SOLUTION: The medicine for swine atrophic rhinitis comprises as an effective ingredient a recombinant Bb-DNT (recombinant Bb-DNT toxoid) detoxified by substituting, with alanine, an amino acid in the transglutaminase active center region of a dermonecrotic toxin (Bb-DNT) produced by Bordetella bronchiseptica. The manufacturing method of the medicine is provided. A mixed vaccine comprising the recombinant Bb-DNT toxoid mixed with another vaccine for swine infectious diseases is also provided. The amino acid substitution is performed at least at one site from among the 1305-, 1320-, 1322-, and 1323-positions in SEQ ID NO.1.  <P>COPYRIGHT: (C)2011,JPO&INPIT
AIMS: Elevated levels of adipokine chemerin have been identified in oral squamous cell carcinoma (OSCC) and found to be associated with metastasis to the cervical lymph nodes. The underlying mechanism through which chemerin affects OSCC progression is unclear. The aims of this study were firstly to determine chemerin levels and cytokine concentrations in serum from patients with OSCC and in OSCC cell cultures, and secondly to observe chemerin effects on OSCC cell cytokine secretion, migration, and invasion in vitro.
METHODS: Serum samples were collected from 20 patients diagnosed with OSCC, including groups with (LN+) and without (LN-) cervical lymph node metastasis. A Luminex liquid suspension assay was used to quantify serum concentrations of 27 types of cytokines. Correlations between chemerin and cytokines (i.e., IL-6, IL-15, GM-CSF, RANTES, TNF-α, and VEGF) were analyzed. ELISAs (enzyme-linked immunosorbent assays) were used to determine concentrations of chemerin and selected cytokines in serum and in supernatants of OSCC cell cultures (SCC9 and SCC25 cell lines). OSCC cells were stimulated with human recombinant chemerin, STAT3 inhibitor, or IL-6 together with TNF-α neutralizing antibodies. Phosphorylated STAT3 protein levels were measured with western blot analysis. OSCC cell migration and invasion were investigated with Transwell assays.
RESULTS: Compared to the LN- group, OSCC patients with cervical lymph node metastasis had higher levels of IL-6 (P = 0.006), IL-15 (P = 0.020), GM-CSF (P = 0.036), RANTES (P = 0.032), TNF-α (P = 0.005), VEGF (P = 0.006), and chemerin (P = 0.001). Patients' serum chemerin levels correlated directly with IL-6, GM-CSF, TNF-α, and VEGF levels in OSCC patients. Exogenous recombinant chemerin treatment promoted secretion of IL-6 and TNF-α via activation of STAT3 in OSCC cells. Chemerin induced OSCC-cell migration and invasion, and these effects were reduced by IL-6 and TNF-α neutralizing antibodies.
CONCLUSION: Our findings indicate that chemerin may play a role in advancing OSCC progression by increasing production of IL-6 and TNF-α, perhaps via a mechanism involving STAT3 signaling.
Using treatment of cetuximab plus chemotherapy. Cetuximab: 500 mg/m2 IV over 2 hours, day 1, every 2 weeks. Chemotherapy: detailed regimen is determined by a multi-disciplinary team.
The invention discloses a polyamine compound and a preparation method and application thereof. The invention discloses a novel trans-acroleic acid derivative, i.e., a compound shown as a formula (I) or a pharmaceutically acceptable salt thereof. The compound shown as the formula (I) in the invention or the pharmaceutically acceptable salt thereof has the activity of selectively inhibiting tumor cells and low toxicity on organisms. The invention further discloses a preparation method of the compound shown as the formula (I). The preparation method is safe, simple and feasible. The compound shown as the formula (I) or the pharmaceutically acceptable salt thereof has a novel structure and high antineoplastic activity, fills up the blank in the field, can be used for preparing an antitumor medicament being used for selectively inhibiting tumor cells and having low toxicity on organisms, and has an important industrial development value and great contribution to the research of anti-cancer medicaments for human beings.
Digital communication technologies are rapidly evolving, and understanding their impact on group dynamics and cognitive performance in professional settings becomes central. This study investigates the psychological impact of different interaction settings-two-dimensional Video Conferencing (VC), Face-To-Face (FTF), and Virtual Reality (VR)-on group dynamics, cognitive performance, and aspects of well-being in a professional context. Utilizing a sample of 40 participants from a large Italian electricity transmission company, the study employs a within-subjects design to explore various metrics, including flow, creativity, fatigue and aspects of interaction. The results indicate that FTF interactions are optimal for idea generation and task absorption. VR, although initially more fatiguing for first-time users, fosters a more collaborative and peaceful environment, encouraging participants to engage more openly with each other. VC was found to be the least fatiguing, but also the least engaging in terms of task absorption and idea generation. Additionally, age-related differences were observed, particularly in the perception of motivational and emotional fatigue in the VR setting. The study provides empirical evidence supporting the integration of VR in professional settings for specific types of meetings, while also highlighting the limitations and areas for future research. These findings have implications for organizational well-being, cognitive ergonomics, and the evolving landscape of remote work technologies.
The invention concerns a human endo type protease 23.32 and polynucleotide encoding it. The invention also concerns the process of producing the polypeptide by recombinant DNA technique. The methods for treating many diseases e.g. malignant tumor, hemopathy, infection of HIV, immunological diseases and a variety of inflammation etc. utilizing the polypeptide are disclosed. The invention discloses the antagonist against the polypeptide and therapeutics thereof. The invention also discloses the uses of the polynucleotide, which encodes a human endo type protease 23.32.
671,500. Therapeutic glandular preparations. REICH, A. March 14, 1950 [March 15, 1949], No. 6371/50. Class 81 (i). A stable therapeutic glandular preparation is made by freezing and then finely pulverizing the fresh sex glands of sexually immature young animals. The resulting powder may be mixed with a dessicant and a water-binding material. Specified dessicants are gelatine or pectin. Flour is a suitable water-binding material. Other therapeutic materials, e.g. pituitary, testicular or ovarian glands or vitamins may be mixed with the product. Examples relate to products obtained from the sex glands of male calfs or pigs or female lambs; but mixed glandular material may also be used. The final product may be in the form of pills or tablets containing sugar and cacao.
IV infusions of 4mg/kg golimumab at Week 0 and every 12 weeks thereafter with early escape (addition of MTX) and dose regimen adjustment (addition of MTX), depending on joint assessment results, at Week 16 and 24, respectively. The duration of the combined IV treatment period (initial treatment plus early escape and/or dose regimen adjustment) will be a minimum of 48 weeks. The IV treatment period will be followed by the option of SC injections of 50mg golimumab every 4 weeks for a further 24 weeks (Extension Study). In addition, patients will receive placebo (sham MTX) capsules.
Endovascular arterial recanalization has become the mainstay therapy for peripheral arterial occlusive disease. Although immediate technical success is achieved in greater than 90% of cases, longer-term results continue to vary based on the clinical presentation, and the treated target lesion. In the current era, sustained patency can be expected following intervention in the carotid, coronary, renal, and iliac arteries. However, maintaining patency in the femoropopliteal and tibial arteries continues to be present a significant challenge. Endovascular intervention in the peripheral arteries is met with heavy complex plaque burdens, multiple serial stenoses and occlusions, sluggish blood flow, low mean and oscillatory shear stress, and repetitive axial, radial and torsional deformation that hinder its outcomes. In order to maximize the longevity of endovascular intervention, its therapeutic armamentarium has developed to include vessel preparation, drug delivery, and arterial scaffolding. Nevertheless, in the aggregate of real-world clinical practice, recurrence of stenosis still complicates up to 50% of all infrainguinal endovascular procedures after only one year. Unfortunately, this timeline is often insufficient to reliably address lifestyle limiting symptoms, heal a wound, or save a threatened extremity. The purpose of this review is to discuss the pathophysiology, incidence, risk factors, morphology and treatment of restenosis following peripheral endovascular intervention.
The present invention is a recombinant vector encoding and expressing at least three or more costimulatory molecules. The recombinant vector may additionally contain a gene encoding one or more target antigens or immunological epitope thereof. The synergistic effect of these costimulatory molecules on the enhanced activation of T cells is demonstrated. The degree of T-cell activation using recombinant vectors containing genes encoding three costimulatory molecules was far greater than the sum of recombinant vector constructs containing one costimulatory molecule and greater than the use of two costimulatory molecules. Results employing the triple costimulatory vectors were most dramatic under conditions of either low levels of first signal or low stimulator to T-cell ratios. This phenomenon was observed with both isolated CD4+ and CD8+ T cells. The recombinant vectors of the present invention are useful as immunogenes and vaccines against cancer and pathogenic micro-organisms, and in providing host cells, including dendritic cells and splenocytes with enhanced antigen-presenting functions.
Adults — The efficacy of SYMBYAX for the acute treatment of depressive episodes associated with Bipolar I Disorder was established in 2 identically designed, 8-week, randomized, double-blind, controlled studies of patients who met Diagnostic and Statistical Manual 4th edition (DSM-IV) criteria for Bipolar I Disorder, Depressed utilizing flexible dosing of SYMBYAX (6/25, 6/50, or 12/50 mg/day), olanzapine (5 to 20 mg/day), and placebo. These studies included patients (≥18 years of age [n=788]) with or without psychotic symptoms and with or without a rapid cycling course.

The primary rating instrument used to assess depressive symptoms in these studies was the Montgomery-Asberg Depression Rating Scale (MADRS), a 10-item clinician-rated scale with total scores ranging from 0 to 60. The primary outcome measure of these studies was the change from baseline to endpoint in the MADRS total score. In both studies, SYMBYAX was statistically significantly superior to both olanzapine monotherapy and placebo in reduction of the MADRS total score. Refer to Table 18 (Studies 1 and 2).

Children and Adolescents — The efficacy of SYMBYAX for the acute treatment of depressive episodes associated with Bipolar I Disorder was established in a single 8-week, randomized, double-blind, placebo-controlled study of patients, 10 to 17 years of age [N=255], who met Diagnostic and Statistical Manual 4th edition-Text Revision (DSM-IV-TR) criteria for Bipolar I Disorder, Depressed. Patients were initiated at a dose of 3/25 mg/day and force-titrated to the maximum dose of 12/50 mg/day over two weeks. After Week 2, there was flexible dosing of SYMBYAX in the range of 6/25, 6/50, 12/25, or 12/50 mg/day. The average daily dose was olanzapine 7.7 mg and fluoxetine 37.6 mg. The recommended starting dose for children and adolescents is 3/25 mg per day. Flexible dosing is recommended, rather than the forced titration used in the study [see Dosage and Administration (2.1)]. This study included patients with or without psychotic symptoms. 

The primary rating instrument used to assess depressive symptoms in these studies was the Children's Depressive Rating Scale-Revised (CDRS-R), a 17-item clinician-rated scale with total scores ranging from 17 to 113. The primary outcome measure of this study was the change from baseline to Week 8 in the CDRS-R total score. In this study, SYMBYAX was statistically significantly superior to placebo in reduction of the CDRS-R total score. Refer to Table 18 (Study 3).
Patients in the Study Group will receive daily treatment for 60 minutes. The treatment is initiated within 24 hours following surgery to achieve graft. Use of Electrical Stimulation by Capacitive Field was the only addition to the current standard of care of the Emergency Unit of HC-FMRP/USP. These Electrical Stimulation by Capacitive Field devices do not produce heat or cause any sensation in tissue. The equipment will produce an electrical stimulation of low intensity pulsed output (1.5 MHz, 1:4 duty cycles, 30mW). The electrodes consist of two metal plates (20x20cm) separated by an insulating material.
Recent advances in the understanding of macrophage biology indicate that tumor-associated macrophages are very heterogeneous and coexist in several distinct subtypes in the tumor microenvironment. These subtypes differ not only in expression profile and origin, but also in their tumorigenic or antitumor function. Here, the inventors describe macrophage subtypes in a mouse model of metastatic melanoma expressing CD 163. Using cytotoxic lipid nanoparticles conjugated with α CD163mAh, specific depletion of CD163 expressing cells in an anti-PD-1 checkpoint inhibitor resistant melanoma model resulted in massive infiltration of CD4+ and activated CD8+ T cells. Furthermore, the inventors showed that combination treatment with anti-PD 1 antibody resulted in rapid tumor recurrence. Accordingly, the present invention relates to a method of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective combination comprising at least one immune checkpoint inhibitor and an agent capable of depleting a CD163+ tumor-associated macrophage population.
FIELD: medicine, cardiology. SUBSTANCE: initial level of P 50  (affinity of hemoglobin to oxygen) at state of rest and P 50  value at the background of maximum impact of tested preparation at condition of inducing stenocardial attack using tests along with physical exercises or via esophageal stimulation. At initial P 50 ≲  23.68 ± 1.30 mm mercury column negative effect of preparations is prognosticated, at initial P 50 ≳  28.56 ± 1.34 mm mercury column positive effect is established. At P 50  ranged 25.00-27.20 mm mercury column P 50  value is additionally determined at loading electrocardiogram tests and repeated esophageal stimulations against maximum impact of preparation. At P 50 ≲ 21.30 ± 1.30 negative forecast is conducted, at P 50 ≳ 23.98 ± 1.36 positive forecast is conducted. EFFECT: higher efficiency of forecasting.
All patients will receive 24 hours of IV Cefazolin, as is universal practice for clean breast surgery. The control group will receive oral outpatient Cefadroxil until the final drain is removed. In case of significant penicillin allergy (defined as a history of urticaria or anaphylaxis associated with penicillin) patients will receive Clindamycin.
Anterior cruciate ligament (ACL) injuries are a severe public health issue from both an economic and general wellness view. This burden will be reduced by promoting compliance and the use of injury prevention programs. To reduce injury rates, trainers, athletes, parents, and the team of sports medicine need to know the advantages of injury prevention programs. Parents and employees in sports medicine want a program that can decrease the risk of injury. Coaches and athletes are looking for a program that will also increase athletic efficiency without taking time off exercise, time that would otherwise be spent honing sport-specific abilities. Injury prevention programs in youth athletics will promote neuromuscular enhancements and create appropriate long-term techniques while instantly preparing the athlete for competition.

Various studies have been done to assess the role of proprioceptive and neuromuscular exercises on reducing incidence of ACL injury. No conclusive result has been established as yet that these type of exercises really reduce the incidence of ACL injury or not. However, it is found that by performing certain exercises there is improvement in biomechanics of jump landing as predicted by LESS score which is a reliable tool to establish risk of ACL and other lower limb injury in an athlete. Therefore the investigators have used a lower limb injury prevention program to assess its effectiveness in reducing LESS score.